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Abstract
Background:  Transgenic mice have been used extensively to analyze gene function.
Unfortunately, traditional transgenic procedures have only limited use in analyzing alleles that cause
lethality because lines of founder mice cannot be established. This is frustrating given that such
alleles often reveal crucial aspects of gene function. For this reason techniques that facilitate the
generation of embryos expressing such alleles would be of enormous benefit. Although the
transient generation of transgenic embryos has allowed limited analysis of lethal alleles, it is
expensive, time consuming and technically challenging. Moreover a fundamental limitation with this
approach is that each embryo generated is unique and transgene expression is highly variable due
to the integration of different transgene copy numbers at random genomic sites.
Results: Here we describe an alternative method that allows the generation of clonal mouse
embryos harboring a single-copy transgene at a defined genomic location. This was facilitated
through the production of Hprt negative embryonic stem cells that allow the derivation of embryos
by tetraploid embryo complementation. We show that targeting transgenes to the hprt locus in
these ES cells by homologous recombination can be efficiently selected by growth in HAT medium.
Moreover, embryos derived solely from targeted ES cells containing a single copy LacZ transgene
under the control of the α -myosin heavy chain promoter exhibited the expected cardiac specific
expression pattern.
Conclusion:  Our results demonstrate that tetraploid embryo complementation by F3 hprt
negative ES cells facilitates the generation of transgenic mouse embryos containing a single copy
gene at a defined genomic locus. This approach is simple, extremely efficient and bypasses any
requirement to generate chimeric mice. Moreover embryos generated by this procedure are clonal
in that they are all derived from a single ES cell lines. This facilitates the comparative analysis of
lethal alleles and thereby advances our ability to analyze gene function in mammals.
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Background
The analysis of gene function during mammalian embry-
onic development relies heavily on the use of transgenic
mice. However, expression of alleles that result in em-
bryonic lethality cannot be studied using regular trans-
genic procedures because lines of founder mice cannot
be established. Analysis of such alleles in mammals has
historically relied upon transient transgenic procedures
[1]. In this approach, fertilized eggs are injected with a
transgene construct and allowed to develop to a pre-de-
termined embryonic stage in utero before being collected
for phenotypic analysis. Using this method a variable
number of transgenes integrate into random genomic lo-
ci. Unfortunately, the local chromosomal environment
can affect expression of the integrated transgene and this
can result in unpredictable transgene expression. More-
over, because no founder line is established it is not pos-
sible to repeat an analysis with a specific transgenic
mouse embryo.
The problem of random transgene integration can be
overcome by targeting transgenes to a specific genomic
locus by homologous recombination in ES cells [2–4]. A
method that allows the introduction of single copy trans-
genes into the X-linked hprt locus has been described
previously by Bronson et al[2]. In this approach single-
copy transgenes are introduced 5' of the hprt locus by ho-
mologous recombination in ES cells. This is an extremely
efficient procedure because targeted clones have recon-
stituted the hprt gene and are selected on the basis of
growth in HAT medium. Following this method, upward
of 90% of HAT resistant ES cell clones contain correctly
targeted transgenes [2]. The hprt locus is a particularly
suitable site for the integration of transgenes because it
exists as an X-linked gene present as a single copy in
male ES cells. Moreover, the hprt gene is ubiquitously
expressed and so provides a favorable chromatin envi-
ronment for transgene expression. Indeed, it has been
demonstrated that the level of expression of transgenes
inserted into the hprt locus is directed solely by exoge-
nous transcriptional regulatory elements [2]. Further-
more, mice derived from independent ES cells clones
containing a transgene expressed from the same promot-
er all exhibit comparable levels of expression [2,4–6].
Although the targeting of constructs to the hprt locus fa-
cilitates consistent expression of transgenes it does not
overcome the need to generate founder lines of transgen-
ic mice. However, pioneering work by Nagy et al has
shown that embryos and mice can be derived directly
from R1 ES cells by aggregating them with tetraploid em-
bryos [7,8]. This suggests that controlled expression of
transgenes encoding possible gain-of-function and de-
velopmental-lethal alleles could be achieved by generat-
ing embryos and/or mice from ES cells containing
transgenes inserted into the hprt locus. Unfortunately,
the generation of mice and embryos by tetraploid aggre-
gation from available Hprt negative ES cell lines has
proven to be inefficient and unreliable (S.A.D. unpub-
lished). In this report, we describe the generation of a
new Hprt negative ES cell line that is compatible with the
tetraploid aggregation procedure. Moreover, we demon-
strate that it facilitates efficient targeting of transgenes
to the hprt locus as well as the subsequent generation of
clonal transgenic mouse embryos that express the trans-
gene in a promoter-dependent manner.
Results
Nagy et al demonstrated that embryos and mice could be
derived solely from R1 ES cells by aggregating them with
tetraploid embryos [7,8]. Although we were able to re-
peat these data using R1 ES cells we were unable to gen-
erate midgestation embryos from E14TG2a-derived
strains of hprt negative ES cell lines using the same ap-
proach [9–11]. We believed it was unlikely that Hprt it-
self was required to generate ES cell-derived embryos
because hprt knockout mice are viable and fertile [12].
E14TG2a-derived ES cell lines contain a large spontane-
ous deletion encompassing 55 kb of the hprt locus [13].
Therefore, it seemed possible that sequences within this
region were necessary to maintain ES cell pluripotency.
However, we believed a more likely scenario was that the
available lines contained unrelated genetic or epigenetic
alterations that were incompatible with the aggregation
procedure. Consistent with this interpretation, Eggan et
al have recently shown that viable offspring are more ef-
ficiently produced through tetraploid-mediated cloning
from outbred ES cell line compared to inbred ES cell
lines [14]. We, therefore, believed it likely that aggrega-
tion-compatible hprt negative ES cells could be generat-
ed by targeted mutation of the hprt gene in R1 ES cells.
To test this we generated a targeting vector to replace
exon 1 of the mouse hprt gene with a neomycin phospho-
transferase (neo) gene that conferred resistance to te
pharmacological inhibitor G418 in ES cells (fig 1a). Fol-
lowing transfection of this plasmid into R1 cells 192
clones that were resistant to G418 were collected and
grown in the presence of 6-thioguanine to select for loss
of Hprt activity. Of the original 192 G418-resistant clones
that were harvested only one, named F3, was also resist-
ant to 6-thioguanine and sensitive to growth in HAT me-
dium (fig 3b). The integrity of the targeting event was
next confirmed by Southern blot analysis of F3 genomic
DNA. As shown in fig 1a the correct integration of Neo at
the hprt locus was predicted to delete a BamH1 restric-
tion endonuclease cut-site from intron 1 and replace it
with a BamH1 site that is unique to the mutant hprt al-
lele. This restriction fragment polymorphism could be
detected using an hprt-specific probe (fig 1a). The wild
type BamH1 fragment was predicted to be 7.0 kb basedBMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
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Figure 1
Generation of HPRT negative ES cells. A) Schematic representation of the hprt genomic locus, targeting vector and mutant
allele. The relative positions of exons (black boxes), BamH1 restriction endonuclease cut sites (b), and genes encoding neomycin
phosphotransferase (neo) and HSV thymidine kinase (HSV-tk) selectable markers, as well as the position of the Southern blot
probe (intron 3 probe) are shown. B) Growth of R1 hprt positive and F3 hprt negative ES cells in medium supplemented with
G418, 6-TG, HAT or without drug (0 drug). Drug resistant ES cells are visible as blue colonies after staining with methyl green
. C) Southern blot analysis of genomic DNA from R1 and F3 ES cells as well from the offspring of chimeric mice generated
from F3 cells. The wild type hprt allele can be identified using intron 3 probe as a 7.0 kb BamH1 fragment and the targeted allele
(mutant) as a 8.3 kb fragment.BMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
Page 4 of 9
(page number not for citation purposes)
on sequence analysis while the mutant fragment should
be 8.3 kb. Fig 1c shows that digestion of wild-type R1 ES
cell DNA with BamH1 did indeed generate a 7.0 kb frag-
ment that could be detected with intron 3 probe. In con-
trast, F3 cells were shown to have replaced this fragment
with an 8.3 kb BamH1 fragment thereby confirming the
integrity of the targeting event.
For F3 cells to be a suitable vehicle for the generation of
transgenic mice they should be competent to generate
Figure 2
Embryos derived from Hprt-deficient ES cells by tetraploid aggregation. A-C) Photographs of embryos at E13.0 derived from
F3 cells. Pigmentation can be seen in the eyes (arrow) reflecting their ES cell origin. D) Southern blot analyses of BamH1-
digested genomic DNA isolated from five (#1 – #5) F3 ES cell-derived embryos that was hybridized to a radiolabeled intron 3
probe. Only the mutant allele is detected in F3 ES cell derived embryos. The wild type allele can be seen in female F3 offspring
as discussed in the text.BMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
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Figure 3
A) Schematic representation of the hprt genomic locus and targeting vector with α -MHC-LacZ insert. The position of a South-
ern blot probe (probe b) containing LacZ specific sequences relative to Xba1 (x) and EcoRV (e) restriction enzyme cut sites is
shown. B) Resistance to growth in HAT and sensitivity to G418 and 6-TG was restored in correctly targeted α  MHC-LacZ ES
cell lines. C) Southern blot analysis of genomic DNA from non-targeted F3 ES cells as well as from six targeted HAT-resistant
ES cell lines generated from F3 cells is shown. The targeted allele is identified using probe b as a 7.0 kb EcoRV fragment. α
MHC-LacZ ES cell line #4 was used to generate embryos shown in D. D) E8.5 embryos derived from α -MHC-LacZ targeted ES
cells by tetraploid aggregation. β -galactosidase expression was identified by x-gal staining (blue). Expression was restricted to
the developing heart (h).BMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
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chimeric mice that can transmit alleles through the
germline. To test the "germline potential" of F3 cells we
first generated chimeric mice by aggregating F3 ES cells
with CD-1 morulae and allowing them to develop to term
in utero. The resulting chimeric males were bred with
CD-1 females and the genotype of offspring determined
by Southern blot analysis of genomic DNA from mouse
tails. Fig 1c shows that agouti F1 female mice contained
both the mutant (paternal) and wild type (maternal) hprt
alleles. In contrast, the agouti F1 male mice contained
only a wild-type hprt allele inherited from the maternal
X-chromosome as expected. From this we were able to
conclude that F3 hprt null ES cells are indeed competent
to transmit alleles through the germline and that the re-
sulting offspring were fertile and viable as reported pre-
viously [12].
We next addressed whether embryos could be generated
solely from F3 Hprt negative ES cells by aggregating
these cells with tetraploid CD-1 embryos and allowing
them to develop in utero until day 13 of gestation (El 3).
Figs 2a,b,c show that F3 cells could indeed give rise to
normal embryos (n = 10). All embryos exhibited charac-
teristic features of midgestation stages of development
including normal rostral-caudal patterning, beating
hearts, normal limb formation including the formation
of fingers. F3 cells derive from the agouti (pigmented)
SV129/J strain of mice. In contrast, albino CD-1 mice do-
nated the tetraploid morulae used in the aggregation
procedure. The finding, shown in figs 2a,b,c, that all the
resulting embryos displayed clear retinal pigmentation
strongly implied that the embryos were F3 ES cell-de-
rived. We confirmed this by determining the genotype of
the embryos by Southern blot analyses of genomic DNA.
Fig 2d shows that all embryos contained a restriction
fragment polymorphism that was indicative of deletion
of hprt exon1. No wild type hprt allele was detected con-
firming that the embryos were generated entirely from
F3 cells. These data demonstrate that the hprt gene is not
essential for the generation of embryos from ES cells by
tetraploid aggregation and that F3 cells should could
provide a suitable vehicle for the direct generation of
transgenic mouse embryos.
Previously it has been shown that a targeting vector,
pMP8, can correct the loss of Hprt activity in E14TG2a
ES cells that lack exons 1 and 2 of the hprt gene [2,15].
The design of this vector implied that it should also be ca-
pable of correcting the hprt exon 1 deficiency in F3 cells
and could, therefore, be used to introduce transgenes
into the hprt locus by homologous recombination. To
test this we generated a modified vector based on pMP8.
The practical features of this modification are that it re-
moves the lacZ sequences in the vector backbone and re-
duces the overall size of the vector, both of which
improve subsequent cloning steps. This vector,
pMP8NEB∆ LacZ, contains a 5' arm of homology consist-
ing of 3.4 kb of mouse 5' hprt genomic DNA flanking a
unique Not1 restriction endonuclease cut site. The 3' arm
of homology contains 1.8 kb of the human hprt gene that
includes exon1 and 2.9 kb of mouse genomic sequence
that includes exon 2 (fig 3a) as described previously [15].
Homologous recombination at the modified hprt locus in
F3 cells should substitute genomic DNA containing hprt
exons 1 and 2 for neo thereby reconstituting a gene en-
coding active Hprt (fig 3a). Moreover, only cells having
undergone a successful homologous recombination
event should become HAT resistant and carry the target-
ed transgene. To assess the efficiency of this approach we
attempted to target a LacZ reporter transgene whose ex-
pression is controlled by the promoter from the alpha
myosin heavy chain (α MHC) gene to the modified hprt
locus in F3 cells. We chose the α MHC promoter because
others have demonstrated, using traditional transgenic
procedures, that it directs high levels of reporter gene ex-
pression specifically in cardiac tissue of early mouse em-
bryos [16–18]. Cells were selected for resistance to HAT
following electroporation of the α MHC-LacZ transgene-
containing plasmid. 16 HAT resistant cells lines were col-
lected and their genotype determined by Southern blot
analysis. Fig 3c shows that, in contrast to F3 cells, a
probe that specifically recognizes the LacZ transgene
identified a 6.7 kb EcoRV fragment in HAT-resistant ES
cell lines. Of the 16 HAT-resistant colonies retrieved 15
contained LacZ. Furthermore, fig 3b shows that these
cells had become G418 and 6-thioguanine sensitive con-
firming that the neo gene had indeed been replaced with
hprt-coding sequences in the F3 cells. These data con-
firm that this selection strategy is extremely efficient in
identifying ES cell clones containing correctly targeted
transgenes [2].
The ultimate use of this procedure is to generate clonal
transgenic mouse embryos directly from the modified ES
cells. Success in this would provide a system in which to
express alleles with potentially lethal phenotypes in the
developing embryo. We, therefore, determined whether
embryos could be generated from the F3 cells that con-
tained an α MHC-LacZ transgene and whether these em-
bryos appropriately expressed β -galactosidase. E8.5
embryos were generated from three independent
α MHC-LacZ cell lines and stained for expression of β -ga-
lactosidase. Representative embryos, shown in fig 3d all
developed normally and expressed high levels of β -galac-
tosidase in the developing heart, mimicking the expres-
sion of endogenous α MHC [16]. Importantly, none of the
embryos exhibited ectopic patterns of expression lending
further support to the proposal that expression of trans-
genes introduced to the hprt locus is primarily depend-BMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
Page 7 of 9
(page number not for citation purposes)
ent on the accompanying transcriptional regulatory
elements [2].
Discussion and conclusions
Here we have described the generation of an ES cell line
and a procedure that will allow the phenotypic analyses
of transgenic embryos expressing lethal alleles. This pro-
cedure is an important addition to the available reper-
toire of molecular genetic techniques available to
developmental biologists because it overcomes several
deficiencies associated with alternative transient trans-
genic approaches normally used to study gain-of-func-
tion and dominant-negative alleles. Traditional
procedures rely on the generation of transgenic embryos
through micro injection of fertilized mouse eggs. Using
this approach an unpredictable number of transgene-
copies are incorporated at a random location in the re-
cipient genome. This can result in ectopic expression of
the transgene because both copy number and the site in-
tegration can influence transgene expression.
In the approach described here, a targeting vector that
contains exon 1 of the hprt gene along with a specific
transgene is used to reconstitute Hprt activity in Hprt
negative ES cells. Successful targeting of the transgene to
the hprt locus in Hprt negative ES cells can be selected by
growing transfected cells in HAT medium. The efficiency
of this selection procedure is such that close to all HAT
resistant colonies contain a correctly targeted transgene.
Moreover, because the transgene is introduced into the
hprt locus its expression is dependent upon the inclusion
of specific transcriptional regulatory elements and re-
mains relatively unaffected by the local chromatin envi-
ronment [2]. A major advantage of this targeted
transgenic approach compared to traditional transgenics
is that transgene expression is predictable so expression
at ectopic sites is largely avoided. The availability of F3
Hprt negative ES cells allows transgenic embryos to be
derived directly from transgenic ES cells by aggregating
the cells with tetraploid embryos and allowing them to
develop in utero. Each embryo is, in effect, clonal be-
cause it is generated from a single clonal ES cell line. This
allows reproducible comparison of the phenotype gener-
ated by a given transgene at different developmental
stages. Moreover, because the transgene is present as a
single copy at a known site of integration it circumvents
the need to generate many different transgenic lines
from a given construct as is the case when using a tran-
sient transgenic procedure.
There are many potential uses for this method of gener-
ating transgenic mouse embryos. The most obvious is
that it provides a mechanism for generating embryos
that express alleles that are predicted, or known, to be
detrimental to normal embryonic development, for ex-
ample dominant-negative or gain-of-function alleles. In-
deed, the expression of dominant negative alleles that
can potentially disrupt multiple members of a gene fam-
ily has been used extensively in Xenopus laevis and has,
for example, helped elucidate the action of fibroblast
growth factors during mesoderm formation [19]. Such
alleles are particularly useful when a null allele in the
same gene causes a disruptive phenotype prior to the
stage of development of interest. Choosing a promoter
that expresses the dominant negative allele later in de-
velopment or in a specific cell type could potentially cir-
cumvent any early phenotype associated with a null
allele.
Another important use of this procedure could be to
identify transcriptional regulatory regions that control
expression of specific genes during development. Trans-
genic mice have been extensively used to identify regula-
tory elements that control gene expression in
vivo[20,21]. This has, in turn allowed the elucidation of
regulatory networks that control cell differentiation dur-
ing development. In this regard, the use of F3 cells cou-
pled with targeting transgenes to the hprt locus offers
two major advantages over traditional transgenic ap-
proaches. The first is that it is extremely rapid. Once the
targeting construct is in hand it takes approximately four
to five weeks to generate transgenic mouse embryos. The
second advantage is due to the presence of the transgene
at a known and constant integration site. This potentially
allows the comparison of levels of reporter gene expres-
sion driven by different promoters thereby offering a
quantitative in vivo transgenic assay.
In sum, the availability of tetraploid aggregation-compe-
tent ES cells that support targeting of transgenes to the
hprt locus should facilitate the rapid analysis of tran-
scriptional regulatory elements in vivo as well as the
phenotypic characterization of alleles that are incompat-
ible with normal development. We, therefore, believe





The targeting plasmid used to delete hprt exon1 was
called p∆ Hprt to indicate this deletion. It was derived
from the plasmid pOS.DUP/DEL that contained the ne-
omycin phosphotransferase (neo) gene that confers re-
sistance to the pharmacological inhibitor G418 and also
contains the Herpes Simplex Virus thymidine kinase
(HSV-TK) that confers sensitivity to gancyclovir. Impor-
tantly the neo gene is flanked by loxP sequences permit-
ting loss of G418 resistance where useful. p∆ Hprt was
constructed by introducing a 2.5 Kb BamHI/HindIIIBMC Biotechnology 2001, 1:12 http://www.biomedcentral.com/1472-6750/1/12
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fragment of 5' hprt genomic DNA (E14TG2a origin) from
the plasmid pMP8 into the Hpa1 site of pOS.DUP/DEL
[15]. The ends of the fragments were made blunt using
Klenow. The 3' arm of homology was introduced into the
unique Bcl1 site of the previous plasmid as a 7 Kb BamHI
fragment from pMP1(SV129 origin) that contained
murine hprt exons 2 and 3.
pMP8NEB∆ LacZ
The plasmid pMP8NEB∆ LacZ was generated by ligating
an 8 kb Xba1 fragment from pMP8 into the Xba1 site of
pNEB193 (New England Biolabs) from which LacZ se-
quences had been removed as a NarI/EcoRI fragment
[15]. This hprt replacement vector contains a 5' arm of
hprt homology consisting of 3.4 kb of mouse 5' hprt ge-
nomic DNA flanking a unique Not1 cloning site. The 3'
arm of homology contains 1.8 kb of the human hprt gene
that includes exon1 and 2.9 kb of mouse genomic se-
quence that includes exon 2. A detailed description of the
pMP8 targeting vector, from which these sequences were
derived, has been described previously [15]. A partial nu-
cleotide sequence of pMP8NEB∆ LacZ is available from
S.A.D. upon request.
pα MHC-LacZ-Hprt
This targeting vector was constructed by inserting a 9.7
kb α MHCLacZ expression cassette into the NotI site of
pMP8NEB∆ LacZ. The 9.7 kb α MHCLacZ expression cas-
sette was constructed by inserting a 3.6 kb SalI/HindIII
fragment from pLacF containing a lacZ gene that incor-
porates a nuclear localization signal into the SalI/HindI-
II site of an α MHC expression module.
ES cell culture, gene targeting and selection
All ES cell lines were cultured on mitotically inactivated
primary embryonic fibroblasts in ES cell medium sup-
plemented with recombinant leukemia inhibitory factor
(LIF) as described elsewhere [22]. F3 cells were generat-
ed by introducing 100 µg of Not1 digested p∆ HPRT plas-
mid into 1.5 ×  108 R1 ES cells by electroporation at 250
volts/500µf/resistance 8 using a BTX ECM600 electro-
poration system [7]. Cells containing neo were selected
by supplementing the ES cell medium with 250 µg/ml
Geneticin (G418, Gibco-BRL) and negative selection
against Hsv-tk gene expression was achieved by includ-
ing 2 µM gancyclovir (Roche). To identify cells that had
lost HPRT activity G418/gancyclovir-resistant colonies
were collected and expanded in 96 well plates in the
presence of 250 µg/ml 6-thiogaunine. Introduction of
transgenes into the hprt locus of F3 cells was achieved
using the following procedure. F3 cells were grown for
two passages in media containing 250 µg/ml 6-thiogua-
nine. 100 µg of linear targeting vector plasmid was intro-
duced into 1.5 ×  108 F3 ES cells by electroporation. Cells
were grown for 2 days before adding HAT (Sigma) to the
growth medium. HAT resistant colonies were harvested
after 10 days growth in HAT-containing medium.
Tetraploid and diploid embryo aggregation
ES-cell derived embryos were generated by aggregating
clumps of around twenty ES cells with individual eight
cell embryos or four cell embryos that had been made
tetraploid by electrofusion as described previously
[7,9,23]. ES cell:embryo aggregates were cultured over-
night and those that formed blastocysts were transferred
to the uteri of psuedo-pregnant females surrogate moth-
ers. To generate chimeric mice the embryos were allowed
to develop to term. ES cell-derived embryos were har-
vested at pre-determined developmental stages and
DNA prepared for Southern blot analysis or fixed and
processed to identify β -galactosidase expression using
standard protocols.
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